Paula Green Sells 291 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 291 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at approximately $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Price Performance

Shares of TWST opened at $96.65 on Friday. The firm has a market capitalization of $6.02 billion, a price-to-earnings ratio of -72.67 and a beta of 2.23. The firm’s fifty day simple moving average is $66.16 and its 200-day simple moving average is $51.10. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $98.40. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.66) EPS. Equities analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TWST shares. TD Cowen increased their price objective on Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a report on Monday, June 15th. Guggenheim raised their price objective on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Canaccord Genuity Group began coverage on shares of Twist Bioscience in a research report on Monday, June 15th. They set a “buy” rating and a $90.00 price objective for the company. Barclays upped their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a research note on Friday, May 22nd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $74.60.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the company. Royal Bank of Canada increased its holdings in shares of Twist Bioscience by 11.8% in the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after acquiring an additional 4,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after purchasing an additional 3,181 shares during the period. Goldman Sachs Group Inc. boosted its stake in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after purchasing an additional 37,577 shares during the period. Intech Investment Management LLC grew its position in Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, Norges Bank purchased a new position in Twist Bioscience during the 2nd quarter worth $737,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.